Phase I/II clinical trial to assess the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase (PARP) -inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; T cell prolymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms PICCLe
- 27 Feb 2016 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials record.
- 06 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by United Kingdom Clinical Research Network.
- 06 Nov 2013 Accrual to date is 20% according to United Kingdom Clinical Research Network.